Central Sensitization Inventory
Also known as: CSI, Central Sensitization Scale
The Central Sensitization Inventory (CSI) is a 25-item self-report screening instrument developed by Mayer and colleagues in 2012 to identify patients with central sensitization—a condition characterized by amplification of pain signaling and hypersensitivity to sensory stimuli. The CSI captures the constellation of symptoms including widespread pain, sleep disturbance, cognitive dysfunction, and autonomic dysregulation associated with central sensitization syndromes such as fibromyalgia, chronic fatigue syndrome, and post-traumatic stress disorder.
Key highlights
- Multidimensional assessment captures the constellation of central sensitization symptoms (pain, sleep, cognitive, affective, autonomic) in a single brief instrument
- Good psychometric properties: Cronbach's alpha ≥0.86-0.90 (internal consistency), test-retest reliability ICC ≥0.79, convergent validity with validated measures of fibromyalgia severity
- Validated in diverse chronic pain populations: fibromyalgia, chronic low back pain, osteoarthritis, chronic fatigue syndrome, PTSD, and other overlapping conditions
- Clinically useful thresholds established (≥40 screening, ≥50 probable central sensitization) with predictive validity for treatment response
- Brief, non-burdensome (3-5 minutes); free and publicly available; increasingly used across disciplines
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
The CSI is indicated for screening patients with widespread pain, chronic fatigue, or overlapping chronic pain syndromes (fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, temporomandibular dysfunction) to identify central sensitization phenotype. It is useful in chronic pain populations where differentiating central from peripheral pain mechanisms informs treatment selection (e.g., high CSI scores favor cognitive-behavioral and neuromodulatory approaches over purely peripheral joint injections). The CSI aids in identifying patients who may benefit from graded exercise therapy, mindfulness interventions, and pharmacotherapy targeting central pain amplification (e.g., pregabalin, duloxetine). Research settings use CSI for phenotyping heterogeneous chronic pain cohorts.
Strengths & limitations
- Multidimensional assessment captures the constellation of central sensitization symptoms (pain, sleep, cognitive, affective, autonomic) in a single brief instrument
- Good psychometric properties: Cronbach's alpha ≥0.86-0.90 (internal consistency), test-retest reliability ICC ≥0.79, convergent validity with validated measures of fibromyalgia severity
- Validated in diverse chronic pain populations: fibromyalgia, chronic low back pain, osteoarthritis, chronic fatigue syndrome, PTSD, and other overlapping conditions
- Clinically useful thresholds established (≥40 screening, ≥50 probable central sensitization) with predictive validity for treatment response
- Brief, non-burdensome (3-5 minutes); free and publicly available; increasingly used across disciplines
- CSI score reflects symptom burden but does not establish mechanism of central sensitization; clinical correlation and often quantitative sensory testing or functional neuroimaging required for confirmation
- Symptom overlap with depression, anxiety, and somatization disorder; high CSI scores alone cannot distinguish central sensitization from primary psychiatric or functional somatic symptom disorders
- Diverse CSI factor structures reported across studies (2-factor to 5-factor solutions), suggesting multidimensional construct may not be unidimensional; subscale stability remains questionable
- Population-specific cutoff values vary; thresholds established in fibromyalgia populations may not apply identically to low back pain or osteoarthritis; context-specific norms recommended
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Does a high CSI score mean the patient has fibromyalgia?
A high CSI score (≥50) indicates probable central sensitization but does not equal fibromyalgia diagnosis. Fibromyalgia requires specific ACR diagnostic criteria including widespread pain for ≥3 months. High CSI scores also occur in other conditions (chronic fatigue syndrome, PTSD, osteoarthritis, chronic low back pain). Clinical assessment, symptom duration, and formal diagnostic criteria are necessary for fibromyalgia diagnosis; CSI is a screening and severity tool, not a diagnostic instrument.
Can CSI scores change with treatment?
Yes. CSI scores decrease with central sensitization-targeted interventions including aerobic exercise, cognitive-behavioral therapy, and medications targeting pain amplification (pregabalin, duloxetine). Typical improvements are 5-15 points over 8-12 weeks with intensive intervention. CSI can also increase if pain and symptom burden worsen. Serial CSI assessments track treatment response.
What is the difference between central sensitization and peripheral nociception?
Peripheral nociception refers to pain arising from tissue damage or inflammation detected by pain receptors (nociceptors); treatments target the tissue problem (e.g., joint injection, anti-inflammatory medication). Central sensitization refers to amplification of pain signals in the nervous system despite normal or minimal peripheral stimulus; treatments target the nervous system (cognitive-behavioral therapy, graded exercise, neuromodulatory medication). Patients often have both; CSI identifies the central sensitization component.
Are there different versions of the CSI, and which should I use?
The 25-item CSI is the standard version published in 2012. A shortened 12-item version exists (CSI-12) developed for rapid screening. The 25-item version is more extensively validated and recommended for clinical and research use. If rapid screening is needed, CSI-12 is acceptable, but confirm with the CSI-12 validation literature for your population.
Sources
- 1.Mayer, T.G., Neblett, R., Cohen, H., et al. (2012). The development and psychometric validation of the Central Sensitization Inventory. Pain Practice, 12(4), 276-285.
- 2.Neblett, R., Cohen, H., Choi, Y., Hardin, J.W., Mayer, T.G., Gonder-Frederick, L.A., & Mayer, J.M. (2013). The Central Sensitization Inventory (CSI): Establishing clinically significant values for identifying central sensitization in an outpatient chronic pain population. Journal of Pain, 14(5), 438-445.
- 3.Schilling, J.M., Koh, S.E., Tully, A.S., et al. (2018). Central sensitization phenotyping in patients with knee osteoarthritis. Clinical Journal of Pain, 34(4), 296-302.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). Central Sensitization Inventory. ScholarGate. https://scholargate.app/pain-medicine/central-sensitization-inventory